Article info

Download PDFPDF

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
  1. Dr D van der Heijde, Department of Rheumatology, LUMC, PO Box 9600, 2300 RC Leiden, The Netherlands; d.vanderheijde{at}kpnplanet.nl
View Full Text

Citation

van der Heijde D, Schiff MH, Sieper J, et al
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

Publication history

  • Accepted August 3, 2008
  • First published August 13, 2008.
Online issue publication 
April 04, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.